首页 | 官方网站   微博 | 高级检索  
     

Clinical Pathologic Study on Effect of Qianggan Capsule (强肝胶囊) in Treating Patients of Chronic Hepatitis B with Liver Cirrhosis
引用本文:杨柳明,赵延龙,吴志荣,陈杜芳,岑卓英,徐克成,左建生,危北海,张万岱.Clinical Pathologic Study on Effect of Qianggan Capsule (强肝胶囊) in Treating Patients of Chronic Hepatitis B with Liver Cirrhosis[J].Chinese Journal of Integrated Traditional and Western Medicine,2002,8(2).
作者姓名:杨柳明  赵延龙  吴志荣  陈杜芳  岑卓英  徐克成  左建生  危北海  张万岱
作者单位:杨柳明,赵延龙,吴志荣,陈杜芳,岑卓英(Department of Liver Diseases, Institute of Integrated Chinese Traditional and Western Medicine, Lianjiang City, Guangdong Province 524400);徐克成,左建生(Yanghe Medical Center, Shenzheng);危北海(Beijing Municipal Institute of TCM);张万岱(South Hospital Affiliated to the First Medical University of PLA) 
基金项目:ItemofthekeyprogramofScienceandTechniqueofZhan jiangCity(No.2 0 0 0 6 8)
摘    要:


Clinical Pathologic Study on Effect of Qianggan Capsule (强肝胶囊)in Treating Patients of Chronic Hepatitis B With Liver Cirrhosis
Abstract:Objective: To explore the clinical therapeutic effect of Qianggan Capsule (QGC) in treating chronic hepatitis B with liver fibrosis from the pathological aspect. Methods: Sixty-three patients of chronic hepatitis B with liver fibrosis were randomly divided into the treated group (n=45) and the control group (n=18). Both groups were treated with general liver protective drugs, such as Glucurone and vitamins B complex for 6 months. To the treated group, QGC was used additionally. The levels of serum alanine transaminase and liver fibrosis indexes including hyaluronic acid (HA), collagen type Ⅳ (C-Ⅳ) and laminin (LN) as well as the pathological examination of liver biopsy were observed before and after treatment. Results: The liver cirrhosis indexes, HA, C-Ⅳ and LN, were improved significantly in the treated group after treatment, P<0.05. The liver function improvement rate in the treated group and the control group was 90.3% and 66.7% respectively, comparison of the two groups showed insignificant difference, P>0.05. Pathological examination showed that the effective rate of treatment on liver inflammatory necrosis activity grade in the treated group was 57.8% and that on liver fibrosis stage was 75.6%, which were significantly improved as compared with those before treatment (P<0.05 and P<0.01), while in the control group, no significant improvement was found after treatment (P>0.05). Conclusion: QGC has marked effects in reversing liver fibrosis and alleviating hepatic inflammatory necrosis in patients of chronic hepatitis B with liver fibrosis, and could lower the serum liver fibrosis related indexes effectively.
Keywords:Qianggan Capsule  chronic hepatitis B  liver fibrosis    pathology
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号